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Abstract
Background: Hepatic fibrosis is a common outcome of hepatic injury in both man and dog.
Activated fibroblasts which develop myofibroblastic characteristics play an essential role in hepatic
fibrogenesis, and are comprised of three subpopulations: 1) portal or septal myofibroblasts, 2)
interface myofibroblasts and 3) the perisinusoidally located hepatic stellate cells (HSC). The present
study was performed to investigate the immunohistochemical characteristics of canine portal
myofibroblasts (MF) and HSC in the normal unaffected liver as a basis for further studies on
fibrogenesis in canine liver disease.
Results: In the formalin-fixed and paraffin embedded normal canine liver vimentin showed staining
of hepatic fibroblasts, probably including MF in portal areas and around hepatic veins; however,
HSC were in general negative. Desmin proved to react with both portal MF and HSC. A unique
feature of these HSC was the positive immunostaining for alpha-smooth muscle actin (α-SMA) and
muscle-specific actin clone HHF35 (HHF35), also portal MF stained positive with these antibodies.
Synaptophysin and glial fibrillary acidic protein (GFAP) were consistently negative in the normal
canine liver. In a frozen chronic hepatitis case (with expected activated hepatic MF and HSC), HSC
were negative to synaptophysin, GFAP and NCAM. Transmission electron microscopy (TEM)
immunogold labelling for α-SMA and HHF35 recognized the positive cells as HSC situated in the
space of Disse.
Conclusion: In the normal formalin-fixed and paraffin embedded canine liver hepatic portal MF
and HSC can be identified by α-SMA, HHF35 and to a lesser extent desmin immunostaining. These
antibodies can thus be used in further studies on hepatic fibrosis. Synaptophysin, GFAP and NCAM
do not seem suitable for marking of canine HSC. The positivity of HSC for α-SMA and HHF35 in
the normal canine liver may eventually reflect a more active regulation of hepatic sinusoidal flow
by these HSC compared to other species.
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Background
Hepatic fibrosis is a common outcome of hepatic injury in
both man and dog. Depending on the primary site of
injury the fibrosis may be restricted to the portal areas as
in most biliary diseases or may be present in the hepatic
parenchyma as seen in chronic hepatitis and cirrhosis.
Chronic hepatitis is often diagnosed in pet-dogs. Treat-
ment provides only limited results and the underlying
mechanism of fibrosis is unclear. Activated fibroblasts
which develop myofibroblasts (MF) characteristics play
an essential role in hepatic fibrogenesis [1]. Three differ-
ent MF-like cells have been described in rat and man
based on location and immunohistochemical profile [2-
4]. These comprise 1) portal or septal MF, present in the
portal areas or in newly formed fibrous septa, 2) interface
MF, present at the interface between parenchyma and
stroma of the portal areas or newly formed fibrous septa,
and 3) the perisinusoidally located hepatic stellate cells
(HSC), also known as vitamin A-storing HSC, Ito-cells,
hepatic lipocytes, lipid-laden cells, fat-storing cells or per-
isinusoidal lining cells. Debate exists regarding the origin
of portal and interface MF and HSC. They may have a
common origin in the primitive mesenchyme of the
embryonal septum transversum. It remains to be eluci-
dated which circumstances then lead to a different pheno-
type for the portal and interface MF and the HSC [5,6]. If
stromal environment may promote transition and differ-
entiation of HSC towards stromal MF, this might have
therapeutic implications in patients.
Although portal and interface MF have been considered to
have fibrogenic potential [7,8], most investigators regard
the HSC as the principal fibrocompetent cell in the liver
[5,9,10]. HSC are located in Disse's space, in between the
hepatocytes and the sinusoidal endothelium, and play an
important role in normal and diseased liver as they 1)
produce the extracellular matrix, 2) act in a pericyte like
manner around the sinusoids thus regulating sinusoidal
blood flow, and 3) are the major site of vitamin-A storage
in lipid vacuoles [9,10].
HSC have species-specific immunohistochemical expres-
sion profiles. All HSC express vimentin (rat), desmin (rat)
and actin (man and rat), but alpha-smooth muscle actin
(α-SMA) is classically considered as an indicator of activa-
tion (man and rat) [6,9,11]. However, in man α-SMA HSC
reactivity proved to be strongly dependent on immunos-
taining conditions [12]. In addition to these myofibrob-
lastic markers, human HSC also display some
neuroendocrine features distinguishing them from the
other hepatic MF-like cells in fibrotic liver [2]. They
express synaptophysin [13], nerve growth factor (NGF),
brain derived nerve growth factor (BDNF), neurotrophin-
3 (NT-3), NT-receptors tyrosine kinase (Trk)-B and -C,
and low-affinity nerve growth receptor p-75 (Trk-A),
while other neuroendocrine markers as neural cell adhe-
sion molecule (NCAM), glial fibrillary acidic protein
(GFAP), NT-4, and alpha B-crystallin are expressed to a
much higher extent in HSC than in the other hepatic MF
subpopulations [2]. With parenchymal injury HSC trans-
fer from a quiescent phenotype into an activated or
transdifferentiated state characterised by increased prolif-
eration, contractility and migration, as well as loss of vita-
min-A containing lipid vacuoles and enhanced expression
of α-SMA and desmin [9,11,14-16]. Furthermore, HSC
produce growth factors as hepatocyte growth factor
(HGF), transforming growth factor beta (TGF-β) as well as
matrix metalloproteinases and abundant amounts of
extracellular matrix components including collagen, pro-
teoglycans and adhesive glycoprotein [5,9,16-18]. In dogs
portal and interface MF and HSC have only been studied
with α-SMA in activated HSC in a CCl4 intoxication model
[19].
The purpose of this study was to investigate immunohis-
tochemical characteristics of canine portal and interface
MF and HSC in the normal unaffected liver, as a basis for
further studies on fibrosis in canine liver disease.
Results
General observations
Routine haematoxylin and eosin (H&E) sections in all
dogs revealed a normal liver. With large individual differ-
ences, presumptive vitamin A-storing HSC were regularly
seen with a single large vacuole (vitamin A-storing lipid
droplet) and a dislocated nucleus. HSC without a vitamin
A-storing vacuole ("empty HSC") could not be identified
on H&E sections. In immunostaining, negative controls
were negative.
Vimentin
There was strong variation between slides. In the portal
area, vimentin showed positive staining cells in smooth
muscle cells of portal vasculature, most spindle-shaped
stromal cells and neural cells (Fig. 1a). Cells in Glisson's
capsule as well as all stromal cells around the sublobular
hepatic vein reacted positively to vimentin antibody.
However, HSC were generally negative, although some
individual positive cells were present (Fig. 1b).
Desmin
There was also marked variation between slides. In gen-
eral, HSC were weakly positive in the perinuclear cyto-
plasm, but vitamin A-storing HSC were predominantly
negative (Fig. 2a). In the portal areas moderate to strong
staining was present in the smooth muscle cells of the
arterial tunica muscularis and in the perivenular smooth
muscle cells of the portal vein (Fig. 2b). In addition, few
positive spindle-shaped stromal cells were seen through-
out the portal stroma and in the periductal location. In theComparative Hepatology 2006, 5:7 http://www.comparative-hepatology.com/content/5/1/7
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sublobular hepatic veins smooth muscle cells were posi-
tive, in the surrounding stroma some MF appeared weakly
positive. Incidentally, some positive cells were seen in
Glisson's capsule.
α-SMA
Consistently in all slides, this marker showed a slightly
irregular (1–3 µm wide) moderate staining in the perisi-
nusoidal spaces throughout the hepatic parenchyma
(Figs. 3a,3b), and with higher magnification positive
staining cells were observed containing small lipid vacu-
oles consistent with HSC (Fig. 3c). Vitamin A-storing HSC
mostly showed positive cytoplasmic staining. Around the
terminal and sublobular hepatic veins positive staining of
pericytes and smooth muscle cells was observed, endothe-
lial cells were consistently negative. Portal areas showed
strong positivity around the bile ducts and in the arterial
tunica media, and moderate positivity in the wall of the
portal veins, while endothelial cells remained negative
(Fig. 3d). Some portal MF, particularly in larger portal tri-
Desmin Figure 2
Desmin. Normal canine liver, stained with desmin antibody. a) A HSC (right) is positive in the perinuclear cytoplasm, weakly 
extending into a cytoplasmic process; also a negative vitamin A-storing HSC (arrow) is present. b) In the portal area, a moder-
ate to strong staining is present in the smooth muscle cells of the arterial tunica muscularis and in the perivenular smooth mus-
cle cells of the portal vein. HSC are weakly positive in the perinuclear cytoplasm.
2a 2b
Vimentin Figure 1
Vimentin. Normal canine liver, stained with vimentin antibody. a) In the portal area, smooth muscle cells of portal vascula-
ture, most spindle-shaped stromal cells and neural cells (arrows) are positive. b) HSC were generally negative, although some 
individual positive cells are present (arrows).
1a 1bComparative Hepatology 2006, 5:7 http://www.comparative-hepatology.com/content/5/1/7
Page 4 of 9
(page number not for citation purposes)
ads, showed weak to moderate α-SMA positivity (Fig. 3d).
Glisson's capsule showed few positive cells.
Muscle-specific actin clone HHF35 (HHF35)
Staining for this marker generally rendered similar results
as α-SMA, consistently in all slides. In the portal areas, the
terminal and sublobular hepatic veins, and in Glisson's
capsule identical staining was observed. In the hepatic
parenchyma moderate positive staining was seen in the
HSC (Figs. 4a,4b). In comparison with α-SMA, HHF35
accentuated the perinuclear cytoplasm. As with α-SMA,
regularly positive staining cells were seen with 1 to 3 small
cytoplasmic lipid vacuoles (Fig. 4a). However, cells with a
single large vitamin A-storing vacuole were mostly nega-
tive (Fig. 4b).
GFAP, synaptophysin and NCAM
In formalin fixed normal canine liver tissue GFAP staining
revealed few positive nerves located in larger portal areas
(internal positive control) but no other positive staining
was observed in any other location in these sections.
Despite strong staining for synaptophysin in the adrenal
medulla (external positive control), no staining was
observed in any of the formalin fixed normal liver sec-
tions. In the frozen chronic hepatitis case (with expected
activated hepatic MF and HSC), only nerves in larger por-
α-SMA Figure 3
α-SMA. Normal canine liver, stained with α-SMA antibody. a) Portal areas show positivity around the bile ducts, in the arte-
rial tunica media, and in the wall of the portal veins. There is slightly irregular moderate staining in the perisinusoidal spaces 
throughout the parenchyma. b) HSC stain positive, producing a thin irregular positive band lining the sinusoids. c) HSC stain 
positive. A positive cell containing one large vacuole (arrow-head is placed in vacuole) and a dislocated nucleus is seen. d) In 
the portal area there is strong positivity around the bile ducts and in the arterial tunica media, and moderate positivity in the 
wall of the portal veins, while endothelial cells remain negative (horizontal arrow). A portal MF with moderate positivity (verti-
cal arrow) is present.
3a 3b
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tal areas reacted positively to GFAP and NCAM, while syn-
aptophysin did not provoke any signal at all.
Immunogold ultrastructural localization
Transmission electron microscopy (TEM) for α-SMA and
HHF35 revealed a strong granular cytoplasmic staining
restricted to subendothelial cells with long cytoplasmic
extensions located in Disse's space (Figs. 5, 6). These cells
often contained several smaller or one larger empty vacu-
ole, interpreted as fat vacuoles (Fig. 5). Very slight, inevi-
table background staining was present in sinusoids and
cells as small irregular spots, to be distinguished from the
positive gold granules by a smaller and more irregular
size. Both location and morphology of the positively
staining cells identified them as HSC.
Discussion
No antibody used in this study is species specific for the
dog, but they still can be used due to interspecies cross-
reactivity. All antibodies have been used previously in
multiple other canine studies [20-26].
Variation in vimentin and desmin staining pattern was
widely present. This might be due to the varying epitope
sensibility, caused by the intrinsic patient material varia-
bility regarding time of postmortal sampling and fixation,
the age of the paraffin blocks, and age, sex and breed var-
iation of the animals. However, the used material reflects
similar variability in intended patient populations to be
studied for spontaneously occurring hepatic fibrosis, and
thus provides useful insight in normal baseline variation.
In the formalin fixed paraffin embedded normal canine
liver vimentin staining did not differentiate between
fibroblasts and MF in the portal area and the perivenous
stromal tissue. Moreover, HSC stained generally negative.
Therefore, we conclude that vimentin antibody is not use-
ful in paraffin sections as a marker for canine portal MF or
HSC. Desmin stained MF in the portal area, around the
sublobular hepatic vein and in Glisson's capsule. HSC
stained inconsistently, with large variation between slides,
so we conclude that desmin is not a sensitive marker for
canine HSC. This is in contrast to man [6], but in accord-
ance to rat [3].
In our laboratory, both α-SMA and HHF35 do identify
myoepithelial cells in canine mammary gland. These
monoclonal antibodies recognise different epitopes: a
NH2 terminal decapeptide (α-SMA), and α and γ muscle
actin (HHF35). The chance of formalin-induced epitope
masking was regarded smaller by use of two different
monoclonal antibodies for the same peptide. Therefore,
both markers were investigated in related (regarding pos-
sible contractility) cells in the liver, being HSC and portal
MF. In formalin fixed paraffin sections these cells can be
easily identified in the normal canine liver by immuno-
histochemical staining for both α-SMA and HHF35. Both
antibodies produced almost identical results and stained
both solitary MF in the portal areas as well as HSC in the
hepatic parenchyma. The presence of small lipid vacuoles
in positively staining perisinusoidal cells as well as the
TEM immunohistochemical results confirms the nature of
the latter cells as HSC. The vitamin A-storing HSC usually
HHF35 (muscle-specific actin, clone HHF35) Figure 4
HHF35 (muscle-specific actin, clone HHF35). Normal canine liver, stained with HHF35 antibody. a) HSC stain positive. 
Cells with few, small vacuoles stain positive (arrowhead). b) HSC stain positive. A vitamin A-storing HSC is negative (arrow).
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stained positive for α-SMA but reacted only rarely to
HHF35, suggesting differentiation in staining characteris-
tics between less contractile vitamin A-storing HSC and
more contractile HSC. The present finding of α-SMA reac-
tivity which was diffusely present throughout the hepatic
parenchyma in the normal canine liver is in contrast with
findings in normal human and rat liver, where the major-
ity of hepatic lobules are devoid of α-SMA positive HSC,
or only show weak positivity [2,6,9,12]. In our opinion,
this indicates a species-specific expression pattern for the
dog. Rat and human HSC upregulate α-SMA expression
upon activation [2,6,28] and this positive staining of acti-
vated HSC is considered to represent increased contractil-
ity of the cells [29,30].
Debate still exists regarding the contribution of non-acti-
vated quiescent HSC to sinusoidal blood flow and blood
pressure in man and rat [9,11]. Our findings of α-SMA
staining in HSC of normal dogs may suggest a more active
role in controlling microvascular blood flow compared to
the rat. Interestingly, the dog is unique in that it has a spi-
rally shaped smooth muscle surrounding the sublobular
hepatic veins consistent with a more active regulation of
the hepatic blood flow in the dog compared to other spe-
cies [31].
Despite positive staining of HSC for α-SMA in normal
dogs reflecting contractility we feel it appropriate to regard
these cells as "quiescent" HSC. This is in line with other
species as HSC are most likely not activated in the sense of
enhanced matrix- or TGF-β production. In the dog dis-
crimination between quiescent and activated HSC does
not seem possible with antibodies directed against α-SMA
and HHF35. However, morphological changes or func-
tional changes such as increased cell size, loss of lipid vac-
uoles and enhanced production of TGF-β and other
substances may be helpful.
The absence of reactivity of portal MF and HSC in the nor-
mal canine liver to synaptophysin and GFAP indicates
TEM of HHF35 (muscle-specific actin, clone HHF35) Figure 6
TEM of HHF35 (muscle-specific actin, clone HHF35). 
Immunogold labelling for HHF35. The positive signal 
(arrows) is present in the subendothelial cellular extensions 
of the hepatic stellate cell situated in Disse's space. E = 
endothelial cell, H = hepatocyte, MV = hepatocytic microvilli, 
S = sinusoid.
MV
HSC
E S
2 µm
6
TEM of α-SMA Figure 5
TEM of α-SMA. Immunogold labelling for α-SMA. The HSC 
is located in Disse's space between the endothelial cell and 
the hepatocyte. It has subendothelial cytoplasmic extensions 
and a prominent large lipid vacuole. The positive signal is 
present in the extensions (arrows). E = endothelial cell, HSC 
= hepatic stellate cell, L = lipid vacuole, S = sinusoid.
S
E
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L
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that in contrast to man and rat [2,3,6], canine portal MF
and HSC do not seem to express the used markers in the
normal liver. Moreover, in frozen sections from a dog
with chronic active hepatitis which likely contained acti-
vated MF and HSC, these cells did also not react to anti-
bodies for neural crest markers NCAM, GFAP and
synaptophysin. As in frozen samples antigens retrieval is
not necessary, we conclude that not only in the quiescent
state but also in the activated state, canine portal MF and
HSC do not bind the used antibodies for NCAM, GFAP
and synaptophysin. Although probably limited by spe-
cies-specificity of the antibodies, this study could be
expanded by the use of more frozen tissue samples, or by
the use of other potential markers, reacting positively on
hepatic MF in other species, like NGF, BDNF, NT-3,
NCAM [2], Foxf1 [32] or fibulin-2 [33].
Conclusion
In formalin fixed paraffin sections, canine portal MF and
HSC can be identified by α-SMA, HHF35 and to a lesser
extent desmin immunostaining. In contrast to man, these
cells are consistently negative for synaptophysin, GFAP
and NCAM, both in formalin-fixed paraffin embedded tis-
sue, as well as in frozen sections. Alpha-SMA and HHF35
positivity of HSC in the normal canine liver may reflect a
more active regulation of hepatic sinusoidal flow by these
cells compared to other species. Alpha-SMA and HHF35
can be used for further studies on hepatic fibrosis in the
dog.
Materials and methods
Dogs
Normal liver tissue was obtained from ten dogs for immu-
nohistochemistry: either patients with liver unrelated
pathology (n = 8) or normal control animals euthanized
for liver-unrelated research projects (n = 2). Laboratory
exams regarding liver function were not performed. One
frozen sample of a dog with chronic hepatitis was addi-
tionally used. Patients were submitted for their individual
diagnostic purposes to the Department of Clinical Sci-
ences of Companion Animals, or to the Department of
Pathology, Faculty of Veterinary Medicine, Utrecht Uni-
versity. No tissue was taken purposely for the reported
study. Projects were approved by the responsible ethical
committees for the use of experimental animals and for
use of client-owned animals according to Dutch legisla-
tion. After euthanasia as part of the research projects, we
were allowed to take liver tissue of the two control ani-
mals. Included were six females and four males. Mean age
was 13 months (± 15 months).
Immunohistochemistry
Liver specimens were taken within 1 hour post mortem (n
= 9), or in a surgical biopsy procedure (n = 1). The normal
liver samples were fixed in 10% neutral buffered formalin
and routinely embedded in paraffin, while the chronic
hepatitis sample was snap-frozen in liquid nitrogen
cooled isopentane and stored at -70°C. Sections (3 µm)
were stained with haematoxylin and eosin for routine his-
tology. Immunohistochemistry was performed for α-
SMA, HHF35, desmin, vimentin, GFAP and synapto-
physin on all normal liver sections, the frozen sections
(chronic hepatitis) were subjected to GFAP, NCAM and
synaptophysin immunohistochemical staining. Antibody
characteristics, manufacturer, source and dilution are
given in Table 1. For this purpose, sections (3 µm) were
mounted on poly-L lysine coated slides and stored for a
maximum of 48 hours at room temperature until use.
After that slides were deparaffinized. Endogenous peroxi-
dase activity was blocked by 1% H2O2 in methanol for 30
min at RT. As the protocols for demonstration of desmin
and synaptophysin required an antigen retrieval step
[13,21] sections were treated by heating in 10 mM citrate
pH 6.0 in a microwave oven for 10 min, cooled down for
10 min at room temperature (RT). After washing with PBS
buffer containing 0.1% Tween-20, background staining
was blocked by incubating the sections with normal horse
serum (1:10 diluted) for 15 min at RT for α-SMA, HHF35,
synaptophysin and vimentin. Desmin and GFAP sections
were blocked with normal goat serum (1:10 diluted) for
15 min at RT. Sections were incubated 60 min at RT with
the primary antibody to α-SMA, desmin, GFAP or HHF35,
and 30 min at RT for vimentin, while sections for synap-
tophysin were incubated overnight at 4°C. After washing
Table 1: Details concerning the used antibodies.
Antibody Manufacturer Catalogue no. Type Clone Dilution Fixative
α-SMA BioGenex MU 128-UC mouse monoclonal clone1A4 1:1200 formalin
Desmin Eurodiagnostica 2203PDE rabbit polyclonal - 1:80 formalin
GFAP ICN Biomedicals 10555 rabbit polyclonal - 1:80 formalin
GFAP Biogenex mouse monoclonal - 1:40 frozen
Muscle actin Dako M0635 mouse monoclonal HHF35 1:300 formalin
NCAM Chemicon rabbit polyclonal 1:50 frozen
Vimentin Dako M0776 mouse monoclonal SY38 1:100 formalin
Synaptophysin Dako rabbit polyclonal - 1:50 frozen
Vimentin Biogenex MU074-UC mouse monoclonal V9 1:150 formalinComparative Hepatology 2006, 5:7 http://www.comparative-hepatology.com/content/5/1/7
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in PBS-Tween, slides to be marked with mouse antibodies
were incubated in horse-anti-mouse biotin (Vector Labo-
ratories, Burlingame, CA, USA) (1:125 diluted) for 30 min
at RT. GFAP and desmin sections were incubated in goat
anti rabbit biotin (1:250 diluted) for 30 min at RT. After
washing in PBS-Tween, sections were incubated in avidin-
biotin peroxidase complex (Vector Laboratories). The col-
our was developed in 3-3'-diaminobenzidine, sections
were counterstained with 10% Mayer's haematoxylin.
Negative controls consisted of omission of the primary
antibody, and replacement by non-immune serum. For-
malin fixed paraffin embedded canine adrenal medulla
served as positive control tissue for synaptophysin. The
other antibodies had internal controls: for GFAP this were
nerves in the larger portal tracts, while for α-SMA, desmin,
HHF35 and vimentin arterial smooth muscle cells served
as positive control tissue.
Immunogold ultrastructural localization
For TEM, additional liver samples were taken from two
female dogs, three and seven years old. Both were normal
control animals euthanized for liver-unrelated research
projects. Projects were approved by the responsible ethical
committees for the use of experimental animals as
required under Dutch legislation. After euthanasia as part
of the projects, we were allowed to take liver tissue. Liver
samples were taken immediately postmortem, fixed in 4%
paraformaldehyde for 2 days, subsequently washed and
transferred in methanol to an auto freezing device from
Reichert. Freeze substitution was performed 36 h at -85°C
in methanol, temperature was gradually raised in 5°C-
steps to -45°C, followed by serial substitution from meth-
anol to Lowicryl HM20 from methanol:HM20 = 2:1 (2 ×
1 h) to methanol:HM20 = 1:2 (2 × 1 h) and pure HM20 2
h at -45°C. Polymerisation was performed for 36 h at -
45°C, then temperature was raised in 5°C-steps for 13 h
up to 20°C. Temperature stayed 20°C for 150 h all under
UV-light. After ultrathin sectioning grids were labelled
according to the procedure for single labelling. Free alde-
hyde groups were blocked in 50 mM glycine in PBS for 15
min, followed by 30 min aurion blocking solution for
goat gold conjugates and washed in BSA-c buffer (PBS +
0.1% BSA-c, pH 7.4), 3 × 5 min. Overnight incubation of
the primary antibodies α-SMA and HHF35 diluted in BSA-
c buffer (1:1200 and 1:300 respectively) was followed by
BSA-c buffer wash (6 × 5 min) and incubation of goat-
anti-mouse IgG ultra small gold diluted 1:50 in BSA-c
buffer (2 h). BSA-c buffer wash (6 × 5 min) and PBS wash
(3 × 5 min) was done previous to postfixation in 2% glu-
taraldehyde in PBS (5 min), followed by wash in PBS (5
min) and distilled water (5 × 2 min). Signal enhancement
was done using Aurion R-Gent SE-EM (30 min), and sub-
sequent washing in distilled water (5 × 2 min). Grids were
then stained with uranyl acetate and lead citrate. For sam-
ple evaluation a Philips CM 10 TEM was used.
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